Companies Dominating the Gastroesophageal Reflux Disease (GERD) Landscape
- AstraZeneca PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eisai Co., Ltd.
- GSK plc.
- Takeda Pharmaceutical Company Limited.
- Ironwood Pharmaceuticals, Inc.
- Johnson & Johnson Services, Inc.
- SFJ Pharmaceuticals
- Sebela Pharmaceuticals
- Phathom Pharmaceuticals, Inc.
- Camber Pharmaceuticals, Inc.
Key players in the market are currently engaged in extensive R&D cohorts to expand their pipeline. They are introducing new safer and long-acting alternatives for better consumer satisfaction and wider adoption. For instance, in April 2024, Onconic Therapeutics gained marketing clearance from the Ministry of Food and Drug Safety (MFDS) of Korea for its next-generation potassium competitive blocker (P-CAB), JAQBO (zastaprazan citrate). This new drug is clinically proven to deliver 97.9% healing for adult GERD patients, just within 8 weeks. Similarly, in December 2024, HK inno.N Corporation announced the commercial launch of its K-CAB (tegoprazan) for GERD in 6 additional Latin American countries. Such key players are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of gastroesophageal reflux disease is evaluated at USD 5.44 billion.
The gastroesophageal reflux disease market size was valued at USD 5.24 billion in 2024 and is set to exceed USD 7.13 billion by 2037, expanding at over 2.4% CAGR during the forecast period i.e., between 2025-2037. Higher consumption of processed food, increase in digestive issues, and problems caused by contaminated food will boost the market growth.
North America industry is predicted to dominate majority revenue share of 35% by 2037, owing to rising aging population in the region which are more prone to gastrointestinal problems.
The major players in the market are AstraZeneca PLC, Eisai Co., Ltd., GSK plc., Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., SFJ Pharmaceuticals, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., Camber Pharmaceuticals, Inc.
